HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J reports Q2

This article was originally published in The Rose Sheet

Executive Summary

Skin care continues to drive performance of firm's consumer business, booking operational growth of 5.9% for fiscal 2009 second quarter. Neutrogena and Aveeno again are standout brands, the latter having launched Nourish+ hair care -- formulated with a wheat protein complex to revitalize damaged hair -- during the quarter (1"The Rose Sheet" March 2, 2009). Firm's U.S. skin-care sales advanced 8.4% operationally, while international sales were up 3.8% partly on strength of products acquired last year from Chinese brand Dabao (2"The Rose Sheet" Aug. 4, 2008, In Brief). Oral-care revenue was down 5.9% in the U.S. due to "softness in the category," but increased 9.5% abroad on an operational basis, with Listerine leading the charge. Overall consumer sales declined 4.5% to $3.9 bil. in what CFO Dominic Caruso calls "one of the most challenging quarters for year-over-year comparisons in [firm's] history" owing to tighter consumer spending, stiffer private-label competition and the loss of market exclusivity as patents expired for J&J drugs including Risperdal and Topomax. However, based on recent launches, approvals and filings with FDA, firm says it has "one of the most robust pharmaceutical pipelines in [its] history." Total company sales in Q2 were $15.2 bil. worldwide, down 7.4%, on a reported basis
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS016292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel